OTC Monograph Application Reviews Get Deadlines, Not GRASE Flexibility
Executive Summary
Changes to FDA's interpretation of the GRASE standard it uses to evaluate ingredient proposals would go further to opening the US monograph process to innovation and progress than setting deadlines for the reviews, industry stakeholders say.
You may also be interested in...
OTC Monograph Reform Proposal Offers Two-Tier Approach
One tier could provide two-year exclusivity, should FDA request clinical trials for new conditions or ingredients, under a US Senate discussion draft. Essentially stalled monograph process would be replaced by deadlines for FDA action in under two years.
Hawaii's Proposed Oxybenzone Sunscreen Ban Fails Science Test – CHPA
CHPA commits to fighting against onslaught of bills in Hawaii aiming to ban or limit the use of oxybenzone-containing sunscreens, says CEO and President Scott Melville during his address on 2017 priorities during the CHPA Annual Executive Conference in Amelia Island, Fla. March 21.
Hawaii's Proposed Oxybenzone Sunscreen Ban Fails Science Test – CHPA
CHPA commits to fighting against onslaught of bills in Hawaii aiming to ban or limit the use of oxybenzone-containing sunscreens, says CEO and President Scott Melville during his address on 2017 priorities during the CHPA Annual Executive Conference in Amelia Island, Fla. March 21.